華邦健康(002004.SZ):擬對普瑞金藥業增資4000萬元 同時擬1.33億元收購其9.9310%股權
格隆匯 9 月 21日丨華邦健康(002004.SZ)公佈,為有力踐行聚焦“大健康”,迴歸醫藥、醫療主業的發展戰略,佈局新型納米抗體藥物,持續強化在皮膚相關疾病領域內的領先優勢,公司於2020年9月21日參與簽署《深圳普瑞金生物藥業有限公司之增資協議》和《深圳普瑞金生物藥業有限公司之股東協議》,以自有資金4000萬元認購深圳普瑞金生物藥業有限公司(以下簡稱“普瑞金藥業”)新增註冊資本68353元;同日,公司與張一卓簽署《深圳普瑞金生物藥業有限公司股權轉讓協議》,以自有資金1.33億元收購張一卓持有的普瑞金藥業9.9310%的股權。本次交易完成後,張一卓不再持有普瑞金藥業股權,公司則直接持有普瑞金藥業12.9067%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.